Mauna Kea Technologies appoints Board Chairman Sacha Loiseau to additional role of CEO

– FRANCE, Paris –  Mauna Kea Technologies (EPA: MKEA | OTC: MKEAY) today announced the appointment of Founder and Board Chairman, Dr. Sacha Loiseau (Ph.D.) to the additional role of CEO, replacing interim CEO Nicolas Bouvier effective immediately.

Mr. Sacha Loiseau will thus hold the positions of Chairman and CEO.

“Our Board has unanimously asked Sacha to return to an executive leadership role where his technical expertise, global relationships, and long-standing commitment to excellence will help ensure that Mauna Kea meets its full commercial and clinical potential,” said Board member, Christopher McFadden.

He added, “Mauna Kea’s partnership strategy seeks to ensure that Cellvizio’s unique clinical value proposition benefits patients globally. Building on announced collaborations with Johnson & Johnson, Telix Pharmaceuticals, On Target Labs, and Tasly Pharma, we have high confidence that Sacha’s leadership will help ensure that the Mauna Kea organization is fully aligned toward meeting our collective obligations to partners, patients, providers, employees, and shareholders.”

About Sacha Loiseau

Sacha Loiseau, a graduate of École Polytechnique and a Ph.D. in Astrophysics, co-founded Mauna Kea Technologies and served as its CEO for more than 18 years, taking the company public in July 2011 Euronext. He has served as Mauna Kea Technologies Chairman of the Board of Directors since October 2018. In addition, Sacha holds other non-executive roles in leading MedTech startups: Chairman of the Board of Therapixel and SeqOne Genomics, Board Member at Lifen, Gleamer, and MDoloris. Sacha is also a Venture Partner with Elaia, a top-tier DeepTech European Venture Capital firm.

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company that manufactures and markets Cellvizio®, the real-time in vivo cell imaging platform. This technology provides unique in vivo cellular visualization that allows physicians to monitor disease progression over time, assess responses as they occur, classify areas of uncertainty and guide surgical interventions. The Cellvizio platform is used in many countries worldwide and in several medical specialties and is transforming how physicians diagnose and treat patients.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.